吉利德:Livdelzi组52周ALP正常化率达75.4%,安慰剂组仅16.1%

投资观察
Nov 05

吉利德科学公司公布了一项积极的III期IDEAL研究结果,进一步支持Livdelzi®(seladelpar)在二线治疗中帮助广泛原发性胆汁性胆管炎(PBC)患者实现ALP正常化目标的作用。数据显示,Livdelzi组有75.4%的患者在第52周实现ALP正常化,而安慰剂组这一比例仅为16.1%。在安全性方面,Livdelzi组严重不良事件发生率为3.1%,安慰剂组则为12.9%;且未出现与药物相关的严重不良事件。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10